MedTrace Logo

Validation of the Prostate Cancer Assay - Beta+Pivotal

NCT02742259 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-03-26

No results posted yet for this study

Summary

The Prostate Cancer Assay performance of Celsee Diagnostics circulating tumor cell (CTC) analysis system will be validated in patients diagnosed with metastatic prostate cancer. It will demonstrate substantial performance equivalency to a CTC Assay predicate device.

Conditions

  • Metastatic Prostate Cancer, CTC

Interventions

DEVICE

Blood Draw

Blood draws only - non-diagnostic, non-treatment

Sponsors & Collaborators

  • Celsee Diagnostics

    lead INDUSTRY

Principal Investigators

  • Yixin Wang, Ph.D. · Celsee Diagnostics

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-04-30
Completion
2017-09-30
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02742259 on ClinicalTrials.gov